Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab : A 52-Week Real-Life Study
© 2024 Martora et al..
Background: The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α drug, the approval of this drug dates to 2015, data provided by real life show an effectiveness rate of about 60% percent. Recently (31 October 2023) FDA approves secukinumab for moderate-severe HS. The treatment and management of HS is very challenging as available treatments are very limited and show very variable outcomes.
Methods: We conducted a prospective monocentric study designed to evaluate the efficacy and safety of secukinumab treatment in HS patients in a real-life setting.
Results: The initial cohort of patients recruited included 21 HS patients including 12 females and 9 males. About 57.1% of patients achieved the primary endpoint and recorded significant decrease in all the severity assessment scales (IHS4, DLQI and VAS pain scale) at week 16 and 52, when HiSCR reached 71.4%.
Conclusion: The results of our study highlight that treatment with secukinumab in patients with severe HS who failed adalimumab may be a safe and effective therapeutic weapon.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Clinical, cosmetic and investigational dermatology - 17(2024) vom: 14., Seite 159-166 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martora, Fabrizio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adalimumab |
|---|
| Anmerkungen: |
Date Revised 31.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/CCID.S449367 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367742101 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367742101 | ||
| 003 | DE-627 | ||
| 005 | 20240131232124.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240129s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/CCID.S449367 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1276.xml |
| 035 | |a (DE-627)NLM367742101 | ||
| 035 | |a (NLM)38283798 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martora, Fabrizio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab |b A 52-Week Real-Life Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 Martora et al. | ||
| 520 | |a Background: The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α drug, the approval of this drug dates to 2015, data provided by real life show an effectiveness rate of about 60% percent. Recently (31 October 2023) FDA approves secukinumab for moderate-severe HS. The treatment and management of HS is very challenging as available treatments are very limited and show very variable outcomes | ||
| 520 | |a Methods: We conducted a prospective monocentric study designed to evaluate the efficacy and safety of secukinumab treatment in HS patients in a real-life setting | ||
| 520 | |a Results: The initial cohort of patients recruited included 21 HS patients including 12 females and 9 males. About 57.1% of patients achieved the primary endpoint and recorded significant decrease in all the severity assessment scales (IHS4, DLQI and VAS pain scale) at week 16 and 52, when HiSCR reached 71.4% | ||
| 520 | |a Conclusion: The results of our study highlight that treatment with secukinumab in patients with severe HS who failed adalimumab may be a safe and effective therapeutic weapon | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adalimumab | |
| 650 | 4 | |a hidradenitis suppurativa | |
| 650 | 4 | |a secukinumab | |
| 650 | 4 | |a treatments | |
| 700 | 1 | |a Marasca, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Cacciapuoti, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Fariello, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Potestio, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Battista, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Scalvenzi, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Megna, Matteo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical, cosmetic and investigational dermatology |d 2008 |g 17(2024) vom: 14., Seite 159-166 |w (DE-627)NLM206946538 |x 1178-7015 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g day:14 |g pages:159-166 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/CCID.S449367 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |b 14 |h 159-166 | ||